Home / Journals / CJU / Vol.18, Suppl.2, 2011
Special Issues
Table of Content
  • Open AccessOpen Access

    EDITORIAL

    Urology Issues and Their Impact on Primary Care Practice

    Jack Barkin
    Canadian Journal of Urology, Vol.18, Suppl.2, pp. 1-1, 2011
    Abstract This article has no abstract. More >

  • Open AccessOpen Access

    ARTICLE

    Erectile dysfunction and hypogonadism (low testosterone)

    Jack Barkin
    Canadian Journal of Urology, Vol.18, Suppl.2, pp. 2-7, 2011
    Abstract Erectile dysfunction (ED) is one of the earliest signs and markers of present or potential future endothelial dysfunction. One of the causes of ED can be low testosterone levels or hypogonadism. This article describes ways to identify and diagnose patients with ED or hypogonadism, and it offers a plan for treatment of these conditions. The mainstay first-line medical therapies for ED are phosphodiesterase-5 (PDE-5) inhibitors. For patients with symptomatic hypogonadism, testosterone replacement therapy is both safe and effective. More >

  • Open AccessOpen Access

    ARTICLE

    Overactive bladder

    Jack Barkin
    Canadian Journal of Urology, Vol.18, Suppl.2, pp. 8-13, 2011
    Abstract Overactive bladder (OAB) is common and has a negative impact on a patient’s quality of life. It is important for physicians to know how to identify and manage patients with this condition. Usually only basic clinical evaluations and a good patient history are necessary to diagnose OAB. Effective and safe oral therapy is available and can be initiated by primary care physicians. More >

  • Open AccessOpen Access

    ARTICLE

    Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management

    Jack Barkin
    Canadian Journal of Urology, Vol.18, Suppl.2, pp. 14-19, 2011
    Abstract Significant lower urinary tract symptoms (LUTS) are very common in men over age 50. It is appropriate for the primary care physician to perform the work up to confirm that benign prostatic hyperplasia (BPH) is causing the LUTS. If the physician determines that the patient has moderate symptoms (an International Prostate Symptom Score [IPSS] ≥ 8), moderate “bother” (≥ 3 on the IPSS “bothersome index” question), and an enlarged (> 30 cc) prostate, then the most effective treatment is combination therapy with an alpha blocker and 5-alpha reductase inhibitor (5-ARI) at the time of confirmed More >

  • Open AccessOpen Access

    ARTICLE

    PSA and the family physician

    Jack Barkin
    Canadian Journal of Urology, Vol.18, Suppl.2, pp. 20-23, 2011
    Abstract The need for men to undergo screening for prostate cancer is controversial. Urologists are concerned about finding many men with minimal disease who may not require therapy or may be over-treated, while conversely missing men with clinically significant prostate cancer that could be treated and cured if found at an early enough stage. Most men today present to the physician with some symptoms attributable to the prostate, and then have a prostatespecific antigen (PSA) test to screen for prostate cancer. PSA is still the most effective test to suggest that there may be underlying prostate… More >

  • Open AccessOpen Access

    ARTICLE

    Pharmacology for common urologic diseases: 2011 review for the primary care physician

    Xiaolong S. Liu1, Christine Folia2, Leonard G. Gomella1
    Canadian Journal of Urology, Vol.18, Suppl.2, pp. 24-38, 2011
    Abstract Coordination of care between the urologist and primary care physician is critical to effective treatment of a variety of urologic conditions. Medical therapies for benign prostatic hyperplasia, erectile dysfunction, hypogonadism, overactive bladder, and prostate cancer are widely available and a basic understanding of the pathophysiology of these disease states as well as the pharmacology of existing treatment options are necessary to avoid complications and maximize efficacy associated with patient outcomes. Important regulatory decisions have been made concerning the approval and lack of approval of several important urologic medications. Major advances have been made in the More >

Per Page:

Share Link